Impacts of the MURANO study for future CLL treatment
Novel technologies to detect minimal residual disease (MRD)
Todd E. Druley
Obinutuzumab (GA101) plus bendamustine as front-line therapy in CLL
What is the potential of daratumumab in combination therapy for myeloma?
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?